Spherical Nucleic Acids in Glioblastoma

We are pleased to share a poster presentation made at the 2019 ASCO Annual Meeting. This presentation contains work by Northwestern University clinicians and scientists demonstrating biodistribution and tolerability data from a Phase 0 first-in-human study of NU-0129, a gold-based SNA targeting the Bcl2L12 gene. The study was conducted in eight patients with glioblastoma brain cancers. The key findings highly relevant for the SNA technology include:

NU-0129 showed initial evidence of crossing blood brain barrier after systemic administration

NU-0129 was well tolerated when given to glioblastoma patients in microdosing with no unexpected adverse effects This patient trial is the first evidence of the SNA technology crossing the blood brain barrier. It also shows delivery into tumors after systemic administration in patients. This is another important milestone in the development of SNA technology, and in our mission to bring genetically targeted drugs to patients in need.

The poster is available for download at the link below.
2019 ASCO Poster on SNA.

Best regards,
David
Copyright © 2019 Exicure, Inc., All rights reserved.
You are receiving this email because you have indicated an interest in receiving information about Exicure, Inc. Our mailing address is:

Exicure, Inc.
8045 Lamon Avenue
Suite 410
Skokie, Il 60077